Combination Therapy Offers Limited Additional Benefit in Type 2 Diabetes
Taking two common types of type 2 diabetes medications together might not protect your heart or kidneys any better…
-
-
Confectionery Consumption Trends Among GLP-1 Users
People taking GLP-1 medications are still buying and enjoying chocolate and candy on a regular basis. Recent research from…
-
What to Expect from Eli Lilly’s Next Earnings Report?
Eli Lilly is currently leading the market in diabetes and weight-loss drugs. A huge chunk of the company’s money…
-
Oral Wegovy Pill Could Expand Access Across South Africa
Novo Nordisk wants a pill version of Wegovy available in South Africa. Supply chains, not just science, explain the…
-
Novo Nordisk Sues Eli Lilly Over Unfair Advertising Claims
Novo Nordisk has filed a lawsuit against Eli Lilly, claiming the rival drugmaker is using misleading ads to market…
-
Could Weight-Loss Drugs Be Curing Our Alcohol Cravings?
It turns out that semaglutide, the active ingredient in popular GLP-1 drugs like Wegovy and Ozempic, does more than…
-
How GLP-1 Weight-Loss Drugs Are Forcing Restaurants to Rethink Their Menus
Weight-loss drugs like Ozempic and Wegovy aren’t just changing waistlines, they are changing how Americans eat out. According to…
-
GLP-1 Medications and Your Teeth: What You Need to Know
GLP-1 medications work wonders for weight loss and managing type 2 diabetes. However, many people don’t realize these popular…
-
Samsung Biologics Offers $1.8 Billion to Acquire PolyPeptide
Samsung Biologics has offered to buy PolyPeptide in an all-cash deal worth approximately $1.8 billion, which translates to $55.17…
-
Market Competitors Reshape Obesity Pharmacotherapy
Novo Nordisk is way ahead in the race for weight-loss pills. The company rolled out its pill version of…
